Mochida Pharma Anti-Depression Drug MHD-55 Enters Phase III Trial
This article was originally published in PharmAsia News
Executive SummaryTokyo-based Mochida Pharma announced that anti-depression drug MHD-55 (escitalopram) has entered Phase III trials. The company's pulmonary arterial hypertension drug MD-0701 (treprostinil), and a cell drug jointly developed with Japan Chemical Research Pharma will enter clinic trials this year. Mochida also plans to start Beselna Cream (imiquimod) clinic trials for additional applications of treating solar kerasotes. Currently imiquimod is a therapeutic agent for condyloma acuminatum. As part of its growth strategy, Mochida has been actively seeking and in-licensing products that have been marketed overseas to add to the company's product lineup. (Click here for more - Japanese language)
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.